Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.
Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy.
Dr. Lori Goldstein from Fox Chase Cancer Center on the Fox Chase Breast Evaluation Center
Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer
October 26th 2011
October 28th 2011
February 4th 2015
